AgomAb Therapeutics (NASDAQ: AGMB) has recently received a number of price target changes and ratings updates:
- 8/25/2026 – AgomAb Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $60.00 price target on the stock.
- 8/25/2026 – AgomAb Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $60.00 price target on the stock.
- 8/19/2026 – AgomAb Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
- 8/15/2026 – AgomAb Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 7/23/2026 – AgomAb Therapeutics is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $34.00 price target on the stock.
AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.
AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.
Featured Stories
- Five stocks we like better than AgomAb Therapeutics
- Boarding Call: EHang Secures First-Mover Altitude
- 3 Space Stocks: Ready for Liftoff or Burning Up on Reentry?
- Space Race Meets Ground Reality for Tower REITs
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
Receive News & Ratings for AgomAb Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.
